HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

4- chloro- N- (1,1,3- trioxo- 2,3- dihydrobenzo(d)isothiazol- 4- yl)benzamide

an antiangiogenic agent; structure in first source

Also Known As:

CLM94

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - Benzothiazoles: 40
        Saccharin: 632
        4-chloro-N-(1,1,3-trioxo-2,3-dihydrobenzo(d)isothiazol-4-yl)benzamide: 2
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzothiazoles: 40
      - Saccharin: 632
        4-chloro-N-(1,1,3-trioxo-2,3-dihydrobenzo(d)isothiazol-4-yl)benzamide: 2

Experts

1.	Antonelli, Alessandro: 2 articles (11/2014 - 04/2012)
2.	Bocci, Guido: 2 articles (11/2014 - 04/2012)
3.	Da Settimo, Federico: 2 articles (11/2014 - 04/2012)
4.	Danesi, Romano: 2 articles (11/2014 - 04/2012)
5.	Fallahi, Poupak: 2 articles (11/2014 - 04/2012)
6.	Ferrari, Silvia Martina: 2 articles (11/2014 - 04/2012)
7.	La Motta, Concettina: 2 articles (11/2014 - 04/2012)
8.	Miccoli, Paolo: 2 articles (11/2014 - 04/2012)
9.	Piaggi, Simona: 2 articles (11/2014 - 04/2012)
10.	Corrado, Alda: 1 article (11/2014)

Related Diseases

1.	Anaplastic Thyroid Carcinoma 04/01/2012 - "CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo." 04/01/2012 - "We have studied the antitumor activity of a novel cyclic amide, CLM94, with anti-vascular endothelial growth factor (VEGF) receptor-2 and antiangiogenic activity in primary anaplastic thyroid cancer (ATC) cells in vitro and in vivo. "
2.	Multiple Endocrine Neoplasia Type 2b (MEN 3) 11/01/2014 - "We report the antineoplastic and anti-angiogenic activity of the pyrazolo[3,4-d]pyrimidine derivative CLM3 and the cyclic amide CLM94, both multiple tyrosine kinase inhibitors (TKIs), in human primary medullary thyroid cancer (P-MTC) cells, and in vitro in the medullary thyroid cancer (MTC) cell lines TT (harboring a RET C634W activating mutation) and MZ-CRC-1 (carrying the MEN2B RET mutation Met891Thr). "
3.	Thyroid Neoplasms (Thyroid Cancer) 04/01/2012 - "CLM94 was tested: 1) in two human cell lines (HMVEC-d, dermal microvascular endothelial cells; and 8305C, undifferentiated thyroid cancer) at 0.001-100 μm; 2) in ATC cells at the concentrations of 10, 30, and 50 μm; and 3) in an ATC cell line (AF) in CD nu/nu mice. "
4.	Neoplasms (Cancer) 04/01/2012 - "CLM94 (40 mg/kg · d) significantly inhibited tumor growth (starting 10 d after the beginning of treatment). " 04/01/2012 - "CLM94 significantly decreased the VEGF-A gene expression in the AF cell line and the VEGF-A protein and microvessel density in AF tumor tissues. "
5.	medullary Thyroid cancer 11/01/2014 - "Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro." 11/01/2014 - "We report the antineoplastic and anti-angiogenic activity of the pyrazolo[3,4-d]pyrimidine derivative CLM3 and the cyclic amide CLM94, both multiple tyrosine kinase inhibitors (TKIs), in human primary medullary thyroid cancer (P-MTC) cells, and in vitro in the medullary thyroid cancer (MTC) cell lines TT (harboring a RET C634W activating mutation) and MZ-CRC-1 (carrying the MEN2B RET mutation Met891Thr). "

Related Drugs and Biologics

1.	Amides
2.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
3.	Proteins (Proteins, Gene)
4.	Antineoplastic Agents (Antineoplastics)
5.	Tyrosine Kinase Inhibitors
6.	pyrimidine